Imugene Limited

Equities

IMU

AU000000IMU9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:04 2024-05-21 am EDT			5-day change	1st Jan Change
0.069 ^AUD	0.00%		-2.82%	-37.27%

Apr. 16	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT
Apr. 16	Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	CI

Imugene doses first patient in PD1-Vaxx combination trial

June 01, 2023 at 11:01 am EDT

(via NewsDirect)

Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong speaks with Proactive soon after announcing the first patient has been dosed in the combination cohort of the IMPRINTER study - a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx in combination with atezolizumab (Tecentriq®) in patients with non-small cell lung cancer. She says Tecentriq® has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the US.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Latest news about Imugene Limited

Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	Apr. 16	MT
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	Apr. 15	CI
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients	Apr. 15	CI
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study	Apr. 14	MT
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China	Apr. 03	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	Mar. 19	MT
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment	Mar. 11	CI
Imugene's Phase 1 onCARlytics Trial to Commence Combination Arm Treatment	Mar. 10	MT
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending	Feb. 28	MT
Imugene Reports H1 FY24 Loss Widens as Expenses Grow	Feb. 28	MT
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Imugene’s Phase 1 onCARlytics Trial Doses First Patient in Intravenous Monotherapy Arm	Feb. 14	MT
Esken's Southend Airport faces further allegations	Jan. 23	AN
MaxCyte Inks Platform License Deal With Cancer Medicine Developer Imugene	Jan. 23	MT
Australian Shares End Five-Day Losing Streak Amid Market Conviction of Early US Fed Pivot	Jan. 19	MT
Imugene’s VAXINIA Metastatic Advanced Solid Tumors Trial Doses First Patients in Higher Dose Cohorts; Shares Up 10%	Jan. 18	MT
Imugene's Vaxinia Trial Shows Positive Signs	Jan. 18	MT
Imugene to Open Phase Two Colorectal Cancer Trial in the UK, Australia	Dec. 06	MT
Imugene to Secure European Patent for Cancer Vaccine	Dec. 05	MT
FDA Grants Fast Track Designation for Imugene's CF33-hNIS in Bile Duct Cancer MAST Program	Nov. 28	MT
US FDA Transfers Cancer Medication Application to Imugene	23-09-28	MT
Imugene Raises AU$18 Million in Share Purchase Plan	23-09-25	MT
Imugene Limited(ASX:IMU) dropped from S&P/ASX 200 Index	23-09-18	CI
Imugene Appoints Medical Chief	23-09-04	MT
Imugene Limited Appoints Paul Woodard as Chief Medical Officer	23-09-03	CI

Chart Imugene Limited

Duration

Period

More charts

Company Profile

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyâs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.069 AUD

Average target price

0.3533 AUD

Spread / Average Target

+412.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMUGENE LIMITED	-37.27%	337M
MODERNA, INC.	+44.48%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-0.86%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	19B
BIO-TECHNE CORPORATION	+7.15%	13B
MEDPACE HOLDINGS, INC.	+29.40%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.19B

Other Biotechnology & Medical Research